BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33880807)

  • 1. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
    J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
    Lou T; Li B; Xiong P; Jin C; Chen Y
    J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
    J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B.
    Voulgaris T; Papatheodoridi M; Lampertico P; Papatheodoridis GV
    Liver Int; 2020 Mar; 40(3):484-495. PubMed ID: 31884726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China.
    Wang S; Liu B; Fan X; Gao Y; Hong M; Xu Y
    Saudi J Gastroenterol; 2022; 28(5):362-368. PubMed ID: 35170433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.
    Wu S; Zhou J; Wu X; Sun Y; Wang B; Kong Y; Zhan S; Jia J; Yang HI; You H
    Am J Gastroenterol; 2022 Sep; 117(9):1444-1453. PubMed ID: 35973147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
    Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
    J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
    Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
    J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
    Gokcen P; Guzelbulut F; Adali G; Degirmenci Salturk AG; Ozturk O; Bahadir O; Kanatsiz E; Kiyak M; Ozdil K; Doganay HL
    World J Gastroenterol; 2022 Feb; 28(6):665-674. PubMed ID: 35317422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
    Kim SU; Seo YS; Lee HA; Kim MN; Kim EH; Kim HY; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):693-699.e1. PubMed ID: 31252188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.
    Wu S; Zeng N; Sun F; Zhou J; Wu X; Sun Y; Wang B; Zhan S; Kong Y; Jia J; You H; Yang HI
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2499-2513. PubMed ID: 33667678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    Kirino S; Tamaki N; Kurosaki M; Inada K; Yamashita K; Sekiguchi S; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Izumi N
    J Viral Hepat; 2021 May; 28(5):787-794. PubMed ID: 33484033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.
    Lee HW; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Liver Int; 2019 Sep; 39(9):1624-1630. PubMed ID: 31050379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
    Yip TC; Wong VW; Lai MS; Lai JC; Tse YK; Liang LY; Hui VW; Chan HL; Wong GL
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2864-2875.e16. PubMed ID: 36828301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals.
    Ji JH; Park SY; Son WJ; Shin HJ; Lee H; Lee HW; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
    J Viral Hepat; 2021 Jun; 28(6):951-958. PubMed ID: 33763928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
    Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
    Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
    Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
    Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.